Shares of Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) were up 11.8% during mid-day trading on Monday. The stock traded as high as $11.37 and last traded at $11.37. 165,709 shares were traded during trading, a decline of 78% from the average session volume of 738,781 shares. The stock had previously closed at $10.17.
Analyst Ratings Changes
IAM has been the topic of a number of research reports. Bank of America started coverage on Iambic Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Iambic Therapeutics in a research note on Monday. They set an “overweight” rating and a $22.00 target price for the company. Jefferies Financial Group began coverage on shares of Iambic Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. Citigroup began coverage on Iambic Therapeutics in a research report on Monday. They issued a “buy” rating and a $22.00 target price for the company. Finally, Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating. According to MarketBeat, Iambic Therapeutics presently has an average rating of “Buy” and an average target price of $27.25.
View Our Latest Stock Analysis on IAM
Iambic Therapeutics Stock Performance
Insider Transactions at Iambic Therapeutics
In other news, Director Evan Lockwood Rachlin acquired 718,750 shares of the company’s stock in a transaction on Friday, October 16th. The shares were bought at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the purchase, the director owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 22.90% of the company’s stock.
About Iambic Therapeutics
Featured Stories
- Five stocks we like better than Iambic Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
